Methods for treatment of Helicobacter pylori -associated...

Details Methods for treatment of Helicobacter pylori -associated... Methods for treatment of Helicobacter pylori -associated...

2007-09-18

2007-09-18

Kam, Chih-Min (Department: 1656)

Drug, bio-affecting and body treating compositions

Designated organic active ingredient containing

Peptide containing doai

C514S012200, C514S017400, C514S018700, C530S300000, C424S009100, C435S243000, C435S007100

Reexamination Certificate

active

10682937

ABSTRACT:
The present invention relates to methods for treating pathological conditions associated withHelicobactersp infections, specificallyH. pyloriinfection. The present invention further relates to methods for treating pathologies characterized by excess gastric acid secretion. The methods of the present invention comprise oral administration of pentagastrin effective locally in the stomach in conjunction with a gastric proton pump inhibitor. It is disclosed herein for the first time that PG administered orally exerts a local effect in the stomach and may be used in combination with a PPI for treating pathological conditions characterized by excess gastric acid secretion and in pathological conditions associated withHelicobactersp infections.

REFERENCES:
patent: 4891356 (1990-01-01), Szabo
patent: 5840737 (1998-11-01), Phillips
patent: 6489346 (2002-12-01), Phillips
patent: 6645988 (2003-11-01), Phillips
patent: 6699885 (2004-03-01), Phillips
patent: 6780882 (2004-08-01), Phillips
patent: 2001/0020005 (2001-09-01), Chowers et al.
patent: 2003/0096012 (2003-05-01), Besse et al.
patent: 1 087 783 (2004-04-01), None
patent: WO99/65513 (1999-12-01), None
patent: WO 01/022985 (2001-04-01), None
patent: WO 01/22985 (2001-04-01), None
Nagata et al. , Antimicrobial Agents and Chemotherapy 39 (2), 567-570 (1995)).
Gaw et al., “Role of pepsin in the development of indomethacin-induced antral ulceration in the rat”,Ailment Pharmacol Ther,vol. 9, pp. 167-172 (1995).
Bonnevie et al., “Double-blind randomized clinical trial of a pepsin-inhibitory pentapeptide (pepstatin) in the treatment of duodenal ulcer”,Gut,vol. 20, pp. 624-628 (1979).
Piper et al., “pH stability and activity curves of pepsin with special reference to their clinical importance”,Gut,vol. 6, pp. 506-508 (1965).
Ayalon, A. et al., “Does Luminal Gastrin Stimulate Gastric Acid Secretion?”Am. J. Surg.,vol. 141, pp. 94-97 (1981).
De Graef, et al., “Influence of the Stimulation State of the Parietal Cells on the Inhibitory Effect of Omeprazole on Gastric Acid Secretion in Dogs,”Gastroenterology,vol. 91, pp. 333-337 (1985).
Fiddian-Green, R.G. et al., “A physiological role for luminal gastrin?”Surgery,vol. 83, No. 6, pp. 663-668 (1978).
Martindale Thirty-second edition, p. 1616, “Supplementary Drugs and Other Substances, 1999.”
Morrell, M.T. et al., “Absorption of Pentagastrin from Gastrointestinal Tract in Man,”Lancet,vol. 2, No. 7937, p. 712 (1975).

Affiliated with

Also associated with

Rating

Methods for treatment of Helicobacter pylori -associated... does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Methods for treatment of Helicobacter pylori -associated..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Methods for treatment of Helicobacter pylori -associated... will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-3800092